PMID- 19578069
OWN - NLM
STAT- MEDLINE
DCOM- 20100224
LR  - 20091117
IS  - 1755-3245 (Electronic)
IS  - 0008-6363 (Linking)
VI  - 84
IP  - 3
DP  - 2009 Dec 1
TI  - A new transmyocardial degradable stent combined with growth factor, heparin, and 
      stem cells in acute myocardial infarction.
PG  - 461-9
LID - 10.1093/cvr/cvp229 [doi]
AB  - AIMS: We developed a new method-transmyocardial drilling revascularization (TMDR) 
      with absorbable stent incorporated with basic fibroblast growth factor (bFGF) and 
      heparin. The present study tested the effect of this method with transplantation 
      of bone marrow-derived stem cells (BMSCs) in acute myocardial infarction. METHODS 
      AND RESULTS: Infarction was produced in mini-swine by ligating the left anterior 
      descending (LAD) coronary artery. TMDR of 3.0 mm in diameter was made by 
      mechanical drilling in the infarcted area. The animals that had LAD ligation were 
      divided into six groups according to the procedures followed (n = 6 in each): 
      control; T (TMDR); C (cell implantation); TS (TMDR+stent implantation); TC 
      (TMDR+cell implantation); TSC (TMDR+stent implantation+cell implantation). Left 
      ventricular (LV) function, myocardial perfusion, vascular density, and 
      histological and morphological analyses were evaluated pre-operatively and at 30 
      min and 6 weeks post-operatively. Six weeks after operation, the above indices 
      were significantly better in the TSC group than in other groups (P < 0.001 
      compared with the control group, and P < 0.05 or 0.01 compared with the TS and TC 
      groups), although TS and TC also showed better results than the control group (P 
      < 0.05). CONCLUSION: We have demonstrated in a pig model that an intramyocardial 
      stent implanted with slow release of bFGF, heparin, and BMSC transplantation may 
      significantly increase LV function, cardiac blood flow, and vascular density. 
      Therefore, the present study may provide a new method for the surgical treatment 
      of myocardial infarction.
FAU - Wang, Ying
AU  - Wang Y
AD  - Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 
      China.
FAU - Liu, Xiao-Cheng
AU  - Liu XC
FAU - Zhang, Guang-Wei
AU  - Zhang GW
FAU - Zhao, Jian
AU  - Zhao J
FAU - Zhang, Jie-Min
AU  - Zhang JM
FAU - Shi, Rong-Fang
AU  - Shi RF
FAU - Huang, Yun-Zhou
AU  - Huang YZ
FAU - Zhao, Chun-Hua
AU  - Zhao CH
FAU - Liu, Tian-Jun
AU  - Liu TJ
FAU - Song, Cun-Xian
AU  - Song CX
FAU - Lu, Feng
AU  - Lu F
FAU - Yang, Qin
AU  - Yang Q
FAU - He, Guo-Wei
AU  - He GW
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20090703
PL  - England
TA  - Cardiovasc Res
JT  - Cardiovascular research
JID - 0077427
RN  - 0 (Fibrinolytic Agents)
RN  - 103107-01-3 (Fibroblast Growth Factor 2)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - *Absorbable Implants
MH  - Animals
MH  - Coronary Vessels/physiology
MH  - Disease Models, Animal
MH  - *Drug-Eluting Stents
MH  - Fibrinolytic Agents/administration & dosage/*therapeutic use
MH  - Fibroblast Growth Factor 2/administration & dosage/*therapeutic use
MH  - Heparin/administration & dosage/*therapeutic use
MH  - *Mesenchymal Stem Cell Transplantation
MH  - Myocardial Infarction/physiopathology/*therapy
MH  - Neovascularization, Physiologic/physiology
MH  - Regional Blood Flow/physiology
MH  - Swine
MH  - Swine, Miniature
MH  - Ventricular Dysfunction, Left/physiopathology/therapy
EDAT- 2009/07/07 09:00
MHDA- 2010/02/25 06:00
CRDT- 2009/07/07 09:00
PHST- 2009/07/07 09:00 [entrez]
PHST- 2009/07/07 09:00 [pubmed]
PHST- 2010/02/25 06:00 [medline]
AID - cvp229 [pii]
AID - 10.1093/cvr/cvp229 [doi]
PST - ppublish
SO  - Cardiovasc Res. 2009 Dec 1;84(3):461-9. doi: 10.1093/cvr/cvp229. Epub 2009 Jul 3.